In Vitro ADME Studies: Laying the Foundation for Preclinical Success

Before a drug can be tested in animals—or ultimately in humans—it must first demonstrate favorable absorption, distribution, metabolism, and excretion (ADME) properties. These pharmacokinetic traits are initially assessed using in vitro ADME studies, which provide essential data for predicting a compound’s performance in vivo.

At InfinixBio, we specialize in designing and executing in vitro ADME studies that inform smarter, faster decision-making during early drug development.

What Are In Vitro ADME Studies?

A scientist with gloves observing a pink substance in a dish

In vitro ADME studies use biological systems outside of living organisms—such as cell cultures, microsomes, and recombinant enzymes—to simulate how a drug might behave in the body. These models allow researchers to predict:

Absorption: Will the compound cross biological membranes (e.g., intestinal, blood brain barrier)?
Distribution: How extensively and where will the compound travel in the body?
Metabolism: Which enzymes will break it down, and into what metabolites?
Excretion: How will the drug and its metabolites leave the body (e.g., renal, biliary)?

These studies are essential for selecting lead candidates, optimizing chemical structures, and minimizing clinical risks.

Core In Vitro ADME Assays

At InfinixBio, we offer a comprehensive suite of in vitro ADME services, including:

Permeability assays (Caco-2, PAMPA)
Plasma protein binding (equilibrium dialysis, ultrafiltration)
Metabolic stability (using liver microsomes, hepatocytes)
Cytochrome P450 inhibition and induction
Transporter interaction studies (e.g., P-gp, BCRP)
Metabolite identification and profiling
Blood-to-plasma ratio and tissue binding

These assays provide mechanistic insight into drug clearance, drug-drug interaction potential, and exposure.

Why It Matters in Preclinical Development

Neglecting ADME liabilities can lead to:

Poor bioavailability
Rapid clearance and short half-life
Unwanted accumulation or off-target toxicity
Failure to meet regulatory safety margins

In vitro ADME data allow drug developers to identify and correct these issues early, long before costly animal or human studies begin.

How InfinixBio Supports ADME Optimization

A scientist looking at a substance underneath a magnifying glass

We help our partners:

Design custom ADME panels based on therapeutic class and modality
Integrate ADME findings with medicinal chemistry for structure-activity relationship (SAR) guidance
Combine in vitro and in silico modeling for predictive PK
Align ADME data with regulatory requirements for IND-enabling packages

Our expert team ensures your compound’s PK profile is optimized and well-understood before it advances into in vivo studies.

Set the Right Course from the Start

In vitro ADME studies are the unsung heroes of preclinical success. With InfinixBio, you get actionable insights early—reducing development risk and improving the odds of clinical viability.